Company intelligence / Profile preview

Progeneer

Not specified directly in sources*, Seoul Special City or Gyeonggi-do region*, South Koreaprogeneer.com ↗

Ownership: Private
Employees: ~33
Development stage: Preclinical

Overview

Progeneer is developing next-generation immunotherapies and vaccines leveraging its proprietary TLR7/8 agonist adjuvant and cell-free protein synthesis platforms. The company has demonstrated strong preclinical results in mounting cell-mediated immune responses with low toxicity, particularly for cancer and infectious disease indications. Clinical trials are being prepared but have not yet commenced as of 2025.[1][2][3]

Therapeutic areas: OncologyInfectious Diseases
Modalities: VaccinesImmunotherapiesAdjuvantsCell-free protein synthesis biologics
Industry: Biotech

Drug pipeline

2 assets

ProV-001

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

FUJIFILM Pharmaceuticals U.S.A. Inc.HLB Biostep

Beyond the preview

Go deeper on Progeneer.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Progeneer.

Explore the full profile